FTC BioPharma M&A Approach Clashes With Sector

The Federal Trade Commission’s approach to merger enforcement in the pharmaceutical and biotech industry has become increasingly aggressive. In this episode of the Votes and Verdicts podcast, Goodwin Procter’s Arman Oruc, co-chair of the company’s antitrust and competition practice, and Bloomberg Intelligence biotech analyst Marc Engelsgjerd join host and BI antitrust litigation analyst Jennifer Rie for a deeper and narrower dive of the FTC’s assessment of dealmaking and the impact on the biopharma sector.See omnystudio.com/listener for privacy information.